HomeCompareSDPNF vs ABBV

SDPNF vs ABBV: Dividend Comparison 2026

SDPNF yields 3.36% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SDPNF wins by $727.53M in total portfolio value· pulled ahead in Year 2
10 years
SDPNF
SDPNF
● Live price
3.36%
Share price
$1.49
Annual div
$0.05
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$727.64M
Annual income
$688,255,421.00
Full SDPNF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SDPNF vs ABBV

📍 SDPNF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSDPNFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SDPNF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SDPNF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SDPNF
Annual income on $10K today (after 15% tax)
$285.38/yr
After 10yr DRIP, annual income (after tax)
$585,017,107.85/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SDPNF beats the other by $584,996,051.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SDPNF + ABBV for your $10,000?

SDPNF: 50%ABBV: 50%
100% ABBV50/50100% SDPNF
Portfolio after 10yr
$363.87M
Annual income
$344,140,096.38/yr
Blended yield
94.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SDPNF
No analyst data
Altman Z
3.8
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SDPNF buys
0
ABBV buys
0
No recent congressional trades found for SDPNF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSDPNFABBV
Forward yield3.36%3.06%
Annual dividend / share$0.05$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$727.64M$102.3K
Annual income after 10y$688,255,421.00$24,771.77
Total dividends collected$724.76M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SDPNF vs ABBV ($10,000, DRIP)

YearSDPNF PortfolioSDPNF Income/yrABBV PortfolioABBV Income/yrGap
1$11,371$671.48$11,550$430.00$179.00ABBV
2← crossover$13,595$1,427.24$13,472$627.96+$123.00SDPNF
3$17,736$3,189.30$15,906$926.08+$1.8KSDPNF
4$26,754$7,777.11$19,071$1,382.55+$7.7KSDPNF
5$50,556$21,928.55$23,302$2,095.81+$27.3KSDPNF
6$131,547$77,452.02$29,150$3,237.93+$102.4KSDPNF
7$517,449$376,694.28$37,536$5,121.41+$479.9KSDPNF
8$3,323,312$2,769,641.14$50,079$8,338.38+$3.27MSDPNF
9$36,804,531$33,248,587.56$69,753$14,065.80+$36.73MSDPNF
10$727,636,269$688,255,421.00$102,337$24,771.77+$727.53MSDPNF

SDPNF vs ABBV: Complete Analysis 2026

SDPNFStock

Sime Darby Plantation Berhad, an investment holding company, engages in the integrated plantations business worldwide. The company operates through Upstream Malaysia, Upstream Indonesia, Upstream Papua New Guinea and Solomon Islands, Downstream, and Other Operations segments. It is involved in the development, cultivation, and management of oil palm, rubber, coconut, and sugarcane plantation estates; milling of fresh fruit bunches into crude palm oil and palm kernel; processing and sale of rubber and sugar; and cattle rearing and beef production activities. The company operates 239 plantation estates covering 744,630 hectares of oil palm plantations, 70 palm oil mills, and 11 refineries. It is also involved in crushing palm kernel into crude palm kernel oils and palm kernel expellers; and manufacturing, blending, marketing, and distributing refined edible oils, specialty fats, special ingredients, tocotrienols, nutraceuticals, oleochemicals, ethanol, biodiesel, oil palm planting materials, and palm oil derivatives. In addition, the company engages in the provision of agriculture products and services, as well as oil palm tissue culture and technical product support services; production and sale of oil palm seeds and seedlings; research, advisory, and breeding programs of oil palm and rubber with special focus on genome science; and development of green technology and renewable energy. Further, it provides commodity trading, raw material procurement, logistics and market risk management, childcare, and local manpower and related services; manufactures and markets rat baits; manufactures and sells various fluidized, hydrolised, fractionated, and compounded lecithin products; owns, operates, and manages rest/guest houses, cafeterias/canteens; and rents conventional and recreational facilities. Sime Darby Plantation Berhad was incorporated in 2004 and is based in Petaling Jaya, Malaysia. Sime Darby Plantation Berhad is a subsidiary of Permodalan Nasional Berhad.

Full SDPNF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SDPNF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SDPNF vs SCHDSDPNF vs JEPISDPNF vs OSDPNF vs KOSDPNF vs MAINSDPNF vs JNJSDPNF vs MRKSDPNF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.